Post
of 161,563
Quote:I'm more focused on Roche, which has a PDL-1 inhibitor, Atezolizumab.
Roche has provided drug to Oncolytics Bio for their metastatic pancreatic cancer trial with pelareorep, a reovirus that also turns cold tumors hot and increases PD-L1 expression. They've had some good results and are working to finalize their registrational trial protocol. No partnership yet.
They've also had good results in HR+/HER2- metastatic breast cancer.
An investigator initiated trial of pelareorep with retifanlimab (PD-L1 inhibitor) in mTNBC is expected to complete end of next month. Will be interesting to see how their results stack up.
7